Inflammatory bowel diseases: a new wave of therapy

Bibliography

• CALKINS BM: A meta-analysis of the role of smoking ininflammatory bowel disease. Dig. Dis. Sci. (1989) 34:1841–1854.
   PubMed Web of Science ®Google Scholar
• PRESENT DH, MELTZER SJ, KRUMHOLZ MP et al.: 6-Mercaptopurine in the management of inflammatory bowel disease: short and long term toxicity. Ann. In-tern. Med. (1989) 111:641–649.
   PubMed Web of Science ®Google Scholar
• SARTOR RB: Current concepts of the aetiology andpathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol. Clin. North Am. (1995) 24:475–507.
   PubMed Web of Science ®Google Scholar
• NEILSON OH, RASK-MADSEN J: Mediators of inflamma-tion in chronic inflammatory bowel diseases. Scand. J. Gastroenterol. (1996) 216:149–159.
   Google Scholar
• LURETSEN K, LAURSEN LS, BUKHAVE K, RASK-MADSEN J:Inhibitors of 5-lipoxygenase and leukotriene forma-tion in inflammatory bowel disease. In: Inflammatory Bowel Diseases. Progress in Basic Research and Clinical. Academic Press, Massachusetts (1991) 325–341.
   Google Scholar
• HAWKEY CJ, DUBE LM, ROUNTREE LV et al.: A trial ofzileuton versus mesalazine or placebo in the mainte-nance of remission of ulcerative colitis. The European Zileuton Study Group for Ulcerative Colitis. Gastroen-terology (1997)112:718–724.
   PubMed Web of Science ®Google Scholar
• MURTHY S, MURTHY NS, COPPOLA D, WOOD DL: The ef-ficacy of Bay Y 1015 in dextran sulfate model of mouse colitis. Inflamm. Res. (1997) 46:224–223.
   PubMed Web of Science ®Google Scholar
• KUMAR, COTRAN, ROBBINS: Basic Pathology (6th Edi-tion). WB Saunders Co. (1997):498–503.
   Google Scholar
• JANEWAY, TRAVERS: Immunobiology: The Immune Systemin Health and Disease. (3rd Edition). Current Biology Ltd./Garland Publishing (1997) G: 1.
   Google Scholar
• DIAZ-GONZALEZ F, SANCHEZ-MADRID F: Inhibition ofleukocyte adhesion: an alternative mechanism of ac-tion for anti-inflammatory drugs. Immunol. Today (1998) 19:169–172.
   PubMedGoogle Scholar
• VAINER B: Role of cell adhesion molecules in inflam- matory bowel diseases. Scand. J. Gastroenterol (1997) 32:401–410.
   PubMed Web of Science ®Google Scholar
• SCHURMANN GM, BISHOP AE, FACER P et al: Increased expression of cell adhesion molecule P-selectin in ac-tive inflammatory bowel disease. Gut (1995) 36:411–418.
   PubMed Web of Science ®Google Scholar
• POOLEY N, GHOSH L, SHARON PA: Up-regulation of E-selectin and intercellular adhesion molecule-1 differs between Crohn's disease and ulcerative colitis. Digest. Dis. Sci. (1995) 40:219–225.
   PubMed Web of Science ®Google Scholar
• NEILSEN OH, BRYNSKOV J, VAINER B: Increased muco-sal concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, and interleukin-8 in active ulcerative colitis. Digest. Dis. Sci. (1996) 41:1780–1785.
   PubMed Web of Science ®Google Scholar
• ARNDT H, PALITZSCH KD, ANDERSON DC et al.: Leukocyte-endothelial cell adhesion in a model of in-testinal inflammation. Gut (1995) 37:374–379.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN, CN, SARGENT M, RAWSTHORNE P et al.: Pe-ripheral blood lymphocyte 132 integrin and ICAM ex-pression in inflammatory bowel disease. Digest. Dis. Sci. (1997) 42:2338–2349.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN CN, SARGENT M, GALLATIN WM: 132 in-tegrin/ICAM expression in Crohn's disease. Clin. Im-munol Immunopathol. (1998) 86:147–160.
   PubMedGoogle Scholar
• NIELSON OH, LANGHOLZ E, HENDEL J et al.: Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease. Digest. Dis. Sci. (1994) 39:1918–1923.
   PubMed Web of Science ®Google Scholar
• PATEL RJ, PALL AA, ADU D et al.: Circulating soluble ad-hesion molecules in inflammatory bowel disease. Eur. Gastroenterol. Hepatol. (1995) 7:1037–1041.
   PubMed Web of Science ®Google Scholar
• WALLACE JL, HIGA A, MCKNIGHT GW et al.: Prevention and reversal of experimental colitis by a monoclonal antibody which inhibits leukocyte adherence. Inflam-mation (1997) 16:343–354.
   Google Scholar
• JONES SC, BANKS RE, HAIDAR A et al: Adhesion mole-cules in inflammatory bowel disease. Gut (1995) 36:724–730.
   PubMed Web of Science ®Google Scholar
• RASK-MADSEN JA: From basic science to future medicaloptions for treatment of ulcerative colitis. Eur. J. Gas-troenterol. Hepatol.(1997) 9:864–871.
   PubMed Web of Science ®Google Scholar
• WATSON SR, FENNIE C, LASKY LA: Neutrophil influx into an inflammatory site inhibited by a soluble hom-ing receptor-IgG chimera. Nature (1991) 349:164–167.
   PubMed Web of Science ®Google Scholar
• ROBERTSON D: Crohn's trial shows the pros of an-tisense. Nature Biotech. (1997) 15:209.
   PubMed Web of Science ®Google Scholar
• YACYSHYN BR, BOWEN-YACYSHYN MB, JEWELL L et al: A placebo-controlled trial of ICAM-1 antisense oligo-nucleotide in the treatment of Crohn's disease. Gastro-enterology (1998) 114:1133–1142.
   PubMed Web of Science ®Google Scholar
• GLOVER JM, LEEDS JM, MANT TG et al: Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).j Pharm. Exp. Ther. (1997) 282:1173–1211.
   PubMed Web of Science ®Google Scholar
• CROOKE ST, GRAHAM MJ, ZUCKERMAN JE et al: Pharma-cokinetic properties of several novel oligonucleotide analogues in mice. J. Pharm. Exp. Ther. (1996) 277:923–937.
   PubMed Web of Science ®Google Scholar
• HENRY SP, NOVOTNY W, LEEDS J et al: Inhibition of co-agulation by a phosphorothioate oligonucleotide. An-tisense Nucleic Acid Drug Devel (1997) 7:503–510.
   PubMedGoogle Scholar
• TARGAN SR, HANAUER SB, VAN DEVENTER SJH et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. New Engl. J. Med. (1997) 337:1029–1035.
   Google Scholar
• STACK WA, MANN SD, ROY A et al.: Randomised con-trolled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet (1997) 349:521–524.
   PubMed Web of Science ®Google Scholar
• RENKONEN R, TURUNEN JP, HAYRY P: Site of influx of inflammatory white cells into a rejecting rat renal allo-graft. Transplantation (1989) 47:577–579.
   PubMed Web of Science ®Google Scholar
• TURUNEN JP, MAJURI ML, SEPPO A et al: De novo expres-sion of endothelial sialyl Lewis (A) and silayl Lewis (x) during cardiac transplant rejection: Superior capaciy-toif, a tetravalent sialyl Lewis (x) oligosaccharide in-hibiting L-selectin dependent lymphocyte adhesion. J. Exp. Med. (1995) 182:1133–1141.
   PubMed Web of Science ®Google Scholar
• BABYATSKY MW, ROSSITER G, PODOLSKY DK: Expres-sion of transforming growth factors a and 13 in colonic mucosa in inflammatory bowel disease. Gastroenterol-ogy (1996) 110:975–984.
   PubMed Web of Science ®Google Scholar
• DINGNASS AU, PODOLSKY DK: Peptide growth factors-implications for IBD. In: Inflammatory Bowel Diseases. Rachmilewitz D (Ed.), Kluwer Academic Publications, Mas-sachusetts (1994) 71–81.
   Google Scholar
• SOTTILI M, STERNINI C, BRECHA C et al.: Transforming growth factor alpha receptor binding site in the canine gastrointestinal tract. Gastroenterology (1992) 103:1427–436.
   PubMed Web of Science ®Google Scholar
• KUROKAWA M, LYNCH K, PODOLSKY DK: Effects of growth factors on an intestinal epithelial cell line: transforming growth factor beta inhibits proliferation and stimulates differentiation. Biochem. Biophys. Res. Commun. (1987) 142:775–782.
   PubMed Web of Science ®Google Scholar
• NEURATH M, MEYER ZUM BUSCHENFELDE KH: Protec-tive and pathogenic roles of cytokines in inflamma-tory bowel diseases. J. Invest. Med. (1996) 4:516–521.
   Google Scholar
• ROSSITER G, PODOLSKY DK: Expression of transform-ing growth factor alpha and beta in colonic mucosa in ulcerative colitis. Gastroenterology (1990) 98:A471.
   Google Scholar
• COFFEY RJ, Jr., GOUSTEN AS, SODERQUIST AM et al.: Transforming growth factor alpha and beta expres-sion in human cancer lines: implications for an auto-crine model. Cancer Res. (1987) 47:4590–4594.
   Google Scholar
• MASSAGUE J: The transforming growth factor beta fam-ily. Ann. Rev. Cell. Biol. (1990) 6:597–641.
   PubMedGoogle Scholar
• CIACCI C, LIND SE, PODOLSKY DK: Transforming growth factor beta regulation of migration in wounded rat intestinal epithelial monolayers. Gastro-enterology (1993) 105:93–101.
   PubMed Web of Science ®Google Scholar
• BRAUCHEL M, MADLENER G, WAGNER AD et al.: Kera-tinocyte growth factor is highly overexpressed in inflammatory bowel disease. Am. J. Pathol. (1996) 149:521–529.
   PubMed Web of Science ®Google Scholar
• FINCH PW, PRISCOLO V, WU A et al.: Increased expression of keratinocyte growth factor messenger RNA associated with inflammatory bowel disease. Gastroenterology (1996) 110:441–451.
   PubMed Web of Science ®Google Scholar
• BAJAJ-ELLIOTT M, BREESE E, POULSON R et al.: Keratino-cyte growth factorininflammatory bowel disease. Am. J. Pathol. (1997) 151:1469–1476.
   PubMed Web of Science ®Google Scholar
• THIM L: A new family of growth factor-like peptides. �Trefoil� disulfide loop structures as a common feature of breast cancer associated peptide (pS2), pancreatic spasmolytic polypeptide (PSP), and frog skin peptides (spasmolysins). FEBS Lett. (1989) 250:85–90.
   Google Scholar
• TAUPIN DR, PANG KC, GREEN SP et al.: The trefoil pep-tides spasmolytic polypeptide and intestinal trefoil factor are major secretory products of rat gut. Peptides (1995)16:1001–1005.
   PubMed Web of Science ®Google Scholar
• HANBY AM, PERA M, FILIPE I et al.: Duodenal content reflux esophagitis in the rat. Am. J. Pathol. (1997) 151:1819–1824.
   PubMed Web of Science ®Google Scholar
• MASHIMO H, WU DC, PODOLSKY DK et al.: Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science (1996) 274:262–265.
   PubMed Web of Science ®Google Scholar
• EGGER B, PROCACCINO F, LAKSHMANAN J et al.: Mice lacking transforming growth factor alpha have an increased susceptibility to dextran sulfate-induced colitis. Gastroenterology (1997) 113:825–832.
   PubMed Web of Science ®Google Scholar
• SARTOR RB, LICHTMAN SN: Mechanisms of systemic inflammation association with intestinal injury. In: Inflammatory Bowel Disease: From Bench to Bedside. Targan SR, Shanahan F (Eds.), Williams & Wilkins, Baltimore (1997) 210–229.
   Google Scholar
• SARTOR RB: Microbial functions inthe pathogenesis of Crohn�s disease, ulcerative colitis and experimental inflammation. In: Inflammatory Bowel Disease. (4th Edition). Kirsner JB, Shorter RG (Eds.), Williams & Wilkins, Baltimore (1995) 96–124.
   Google Scholar
• WILSON AJ, GIBSON PR: Epithelial migration in the colon: filling in the gaps. Clin. Sci. (1997) 93:97–108.
   PubMed Web of Science ®Google Scholar
• NUSRAT A, PARKOS CA, LIANG TW et al.: Neutrophil migration across model intestinal epithelia: monolayer disruption and subsequent events in epithelial repair. Gastroenterology (1997) 113:1489–1500.
   PubMed Web of Science ®Google Scholar
• SINGER II, KAWAKA DW, SCOTT S et al.: Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology (1995) 30:784–788.
   Google Scholar
• GRISHAM MB, WARE K, GILLELAND HE, JR. et al.: Neutrophil-mediated nitrosamine formation: role of nitric oxide in rats. Gastroenterology (1992) 103:1260–1266.
   Google Scholar
• OUDERKM, BOUMA G, VISSER JJet al.: Serum nitrate levels in ulcerative colitis and Crohn�s disease. Scand. J. Gastroenterol. (1995) 30:784–788.
   Google Scholar
• MURTHY S, GUPTA M, MURTHY N: Implications of reactive oxygen metabolites in inflammatory bowel diseases. In: Oxygen Radicals and the Disease Process. Thomas CE, Kalyanaraman B (Eds.), Harwood Academic Publishers, Australia (1997) 101–126.
   Google Scholar
• MATRISIAN LM: The matrix-degrading metalloprote-inases. Bioessays (1992) 14:455–463.
   PubMed Web of Science ®Google Scholar
• WOESSNER JF, Jr.: Matrix metalloproteinases and their inhibitor in connective tissue remodelling. FASEB J. (1991) 5:2145–2154.
   PubMed Web of Science ®Google Scholar
• GELLER SA: Pathology of inflammatory bowel disease: a critical appraisal in diagnosis and management. In: Inflammatory Bowel Disease: from Bench to Bedside. Targan SR, Shanahan F (Eds.), Williams & Wilkins, Baltimore (1994) 336–351.
   Google Scholar
• TURNER NC, WOOD LJ, BURNS FM et al.: The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst. Br. J. Pharmacol. (1993) 108:876–883.
   PubMed Web of Science ®Google Scholar
• UNDERWOOD SL, LEWIS SA, RAEBURN D: RP 58802B, a long acting beta 2- adrenoceptor agonist: assessment of antiasthma activityin the guinea pig in vivo. Pulmon. Pharmacol. (1992) 5:203–212.
   PubMedGoogle Scholar
• KNIGHT CG, WILLENBROCK F, MURPHY G: A novel coumarin-labeled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. (1992) 296:263–266.
   PubMed Web of Science ®Google Scholar
• BRUCE AN: Vaso-dilator axon-reflexes. Quart. J. Exp. Physiol. (1913) 6:339–354.
   Google Scholar
• LEWIST: The nocifensor system of nerves and its reactions. Br. Med. J. (1937) 1:431–435.
   PubMedGoogle Scholar
• LEWIST: The nocifensor system of nerves and its reactions. Br. Med. J. (1937) 1:491–497.
   PubMedGoogle Scholar
• JANSCO N, JANSCO-GABOR A, SZOLCSANYI J: Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br. J. Pharmacol. Chemother. (1967) 31:138–151.
   PubMed Web of Science ®Google Scholar
• MANTYH PW: Substance P and the inflammatory and immune response. In: Substance P, and Related Peptides: Cellular and Molecular Physiology. Leeman SE, Krause JE, Lembeck F (Eds.), New York Academy Science, USA (1991) 263–271.
   Google Scholar
• OTSUKA M, YOSHIOKA K: Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. (1993) 73:229–308.
   PubMed Web of Science ®Google Scholar
• MAGGI CA: The effectsoftachykininsoninflammatory and immune cells. Reg. Pept. (1997) 70:75–90.
   PubMed Web of Science ®Google Scholar
• WEIHE E, NOHR D, MULLER S, BUCHLER M, FRIESS H, ZENTEL HJ: The tachykinin neuroimmune connection in inflammatory pain. In: Substance P, and Related Pep-tides: Cellular and Molecular Physiology. Leeman SE, Krause JE, Lembeck F (Eds.), New York Academy Science, USA (1991) 283–295.
   Google Scholar
• LUNDBERG JM, SARIA A: Capsaicin-induced desensitisa-tion of airway mucosa to cigarette smoke, mechanical and chemical irritants. Nature (1983) 302:251–253.
   PubMed Web of Science ®Google Scholar
• UNDEM BJ, MYERS AC: Neural regulation of the immuneresponse. In: Asthma and Rhinitis. (2nd Edition). Holgate ST, Busse WW (Eds.), Blackwell Science Publishers (1997).
   Google Scholar
• LADDUWAHETTY T, BAKER R, CASCIERI MA et al: N-heteroary1-2-pheny1-3-(benzyloxy0 piperidines: a novel class of potent orally active human NK1 antago-nists. J. Med. Chem. (1996) 39:2907–2914.
   PubMedGoogle Scholar
• EL-SHAZLY AE, MASUYAMA K, EURA M et al.: Immu-noregulatory effect of substance P in human eosino-phil migratory function. Immun. Invest. (1996) 25:191–201.
   PubMed Web of Science ®Google Scholar
• GAO GC, WET ET: Inhibition of substance P-inducedvascular leakage in rat by N-acetyl-neurotensin-(8-13). Reg. Pept. (1995) 58:117–121.
   PubMedGoogle Scholar
• WALSH DT, WEG VB, WILLIAMS TJ et al.: Substance P-induced inflammatory responses in guinea pig skin: the effect of specific NK1 receptor antagonists and the role of endogenous mediators. Br. J. Pharm. (1995) 114:1343–1350.
   PubMed Web of Science ®Google Scholar
• WALLACE JL, MCCAFFERTY DM, SHARKEY KA: Lack ofbeneficial effect of a tachykinin receptor antagonist in experimental colitis. Reg. Pept. (1998) 73:95–99.
   PubMedGoogle Scholar
• SEN R, BALTIMORE D: Multiple nuclear factors interactwith the immunoglobulin enhancer sequences. Cell (1986) 46:705-716. SIEBENLIST U, FRANZOSO G, BROWN K: Structure, regu-lation and function of NF-KB. Cell Biol. (1994) 10:405-455. BAEUERLE PA, BALTIMORE D: NF-KB: ten years after. Cell (1996) 87:13-20. KOPP EB, GHOSH S: NF-KB and rel proteins in innate immunity. Adv. Immun. (1995) 58:1-27. ELLIOT MJ, MAINI RN, FELDMANN M: Randomised double-blind comparison of chimeric monoclonal an-tibody to tumor necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105–1109.
   Google Scholar
• ZHU Z, TANG W, RAY A. Rhinovirus stimulation of in- terleukin 6 in vivo and in vitro: evidence for nuclear factor KB-dependent transcriptional activation. J. Clin. Invest. (1996) 97:421–430.
   Google Scholar
• STEIN B, BALDWIN AS, JR.: Distinct mechanisms for regulation of the interleukin-8 gene involves syner-gism and cooperativity between C/EBP and NF-KB. Mol. Cell. Biol. (1993) 13:7191–7198.
   Google Scholar
• XIE QW, KASHIWABARA Y, NATHAN C: Role of tran- scription factor NF-KB/Rel in induction of nitric oxide synthase. J. Biol. Chem. (1994) 269:4705–4708.
   PubMed Web of Science ®Google Scholar
• RACHMILEWITZ D, STAMLER JS, BACHWICH D et al.: En- hanced colonic nitric oxide generation and nitric ox-ide synthase activity in ulcerative colitis and Crohn's disease. Gut (1995) 36:718–723.
   PubMed Web of Science ®Google Scholar
• LUNDBERG J, HELLSTROM PM, LUNDBERG JM et al.: Greatly increased luminal nitric oxide in ulcerative co-litis. Lancet (1994) 344:1673–1674.
   PubMed Web of Science ®Google Scholar
• ALBEDA SM, SMITH CW, WARD PA: Adhesion molecules and inflammatory injury. FASEB (1994) 8:504–512.
   PubMed Web of Science ®Google Scholar
• SCHRECK R, RIEBER P, BAUERELE PA: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-KB transcription factor and 11IV-1. EMBO J (1991) 10:2247–2258.
   PubMed Web of Science ®Google Scholar
• NEURATH MF, PETTERSON S, MEYER ZUM BUSCHEN-FELDE KH, STROBER W: Local administration of an-tisense phosphorothioate oligonucleotides to the p65 subunit of NF-KB abrogates established experimental colitis in mice. Nature Med. (1996) 2:998–1004.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, NIKOLAUS S, HAMPE J: Activation of nu-clear factor KB in inflammatory bowel disease. Gut (1998) 42:477–484.
   PubMed Web of Science ®Google Scholar
• CONNER EM, BRAND SJ, DAVIS JM et al.: Role of reactivemetabolites of oxygen and nitrogen in inflammatory bowel disease: toxins, mediators and modulators of gene expression. InfIamm. Bowel Dis. (1996) 2:133–147.
   PubMed Web of Science ®Google Scholar
• CONNER EM, BRANDS, DAVIS JM etal.: Proteosome inhi-bition attenuates nitric oxide synthase expression, VCAM transcription and the development of chronic colitis. J. Exp. Pharmacol Ther. (1997) 282:1615–1622.
   Google Scholar
• PAHL HL, KRAUSS B, SCHULZE-OSTHOFF K: The immu-nosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-KB. J. Exp. Med. (1996) 183:1829–1840.
   PubMed Web of Science ®Google Scholar
• YANG JP, MERIN JP, NAKANO T et al.: Inhibition of the DNA-binding activity of NF-KB by gold compounds in vitro. FEBS Lett. (1995) 361:89–96.
   PubMed Web of Science ®Google Scholar
• WANG P, WU P, SIEGEL MI et al.: Interleukin (IL-10) in-hibits nuclear factor kappa B (NF-KB) activation in hu-man monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J. Biol. Chem. (1995) 270:9558–9563.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, HEINIG T, THIELE HG, RAEDLER A: Immu-noregulatory role of interleukin-10 in patients with in-flammatory bowel disease. Gastroenterolgy (1995) 108:1434–1444.
   PubMed Web of Science ®Google Scholar
• SCHEINMAN RI, COGSWELL PC, LOFQUIST AK et al: Roleof transcriptional activation by IKB in mediation of im-munosuppression by glucocorticoids. Science (1995) 270:283–286.
   PubMed Web of Science ®Google Scholar
• SHA WC, LIOU HC, TOUMANEN El et al: Targeted disrup-tion of the p50 subunit of NF-KB leads to multifocal de-fects in immune responses. Cell (1995) 80:321–330.
   PubMed Web of Science ®Google Scholar
• BEG AA, SHAW WC, BRONSON RT et al.: Embryonic le-thality and liver degeneration in mice lacking the Rel A component of NF-KB. Nature (1995) 376:167–170.
   PubMed Web of Science ®Google Scholar
• GRIMMM C, DOE WF: Chemokines in inflammatory bowel disease mucosa: expression of RANTES, macro-phage inflammatory protein (MII) -1, MIP-1, and interferon-inducible protein-10 by macrophages,
   Google Scholar
• ROLLINS B J: Chemokines. Blood (1997) 90:909–928.
   PubMedGoogle Scholar
• LUSTER, A: Chemokines-chemotactic cytokines that mediate inflammation. New Engl. J. Med. (1998) 338:436–445.
   PubMed Web of Science ®Google Scholar
• WELLS TNC, POWER CA, LUSTI-NARASIMHAM M et al.: Se-lectivity and antagonism of chemokine receptors. J. Leukocyte Biol. (1996) 59:53–60.
   PubMed Web of Science ®Google Scholar
• LOETSCHER P, SEITZ M, BAGGIOLINI M et al.: Interleukin-2 regulates CC chemokine receptor ex-pression of C-C chemokine receptors in human mono-cytes. J. Exp. Med. (1996) 184:569–577.
   PubMed Web of Science ®Google Scholar
• MCFADDEN G, KELVIN D: New Strategies for Che-mokine Inhibition and Modulation. Biochem. Pharma-col. (1997) 54:1271–1280.
   PubMed Web of Science ®Google Scholar
• REINECKER HC, LOH EY, RINGLER DJ et al.: Monocyte-chemoattractant protein 1 gene expression in intesti-nal epithelial cells and inflammatory bowel disease mucosa. Gastroenterology (1995) 108:40–50.
   PubMed Web of Science ®Google Scholar
• GRIMM MC, ELSBURY S, PAVLI P et al: Enhanced expres-sion and production of monocyte chemoattractant protein-1 in inflammatory bowel disease mucosa. J. Leukocyte Biol. (1996) 59:804–812.
   PubMed Web of Science ®Google Scholar
• GARCIA-ZEPEDA EA, ROTHENBERG ME, OWNBEY RT et al.: Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to ex-plain tissue eosinophilia. Nature Med. (1996) 4:449–456.
   Google Scholar
• MAZZUCCHELLI U, HAUSER C, ZGRADDEN K: Differen-tial in situ expression of the genes encoding the che-mokines MCP-1 and RANTES in human inflammatory bowel disease. J. Pathol (1996) 178:201–206.
   PubMed Web of Science ®Google Scholar
• MULLIN GE, SCHMIDT A, BRAUN-ELWERT L et al: RAN-TES, MCAP and MIP-2 alpha mRNA levels are increased in the mucosal lesions of IBD. Gastroenterology (1994) 106:A741.
   Web of Science ®Google Scholar
• MAZZUCCHELLI L, HAUSER C, ZGRAGGEN K et al. Ex-pression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active in-flammation. Am. J. Pathol. (1994) 144:997–1007.
   PubMed Web of Science ®Google Scholar
• BAGGIOLINI M, MOSER B: Blocking chemokine recep-tors. J. Exp. Med. (1997) 186:1189–1191.
   PubMed Web of Science ®Google Scholar
• SARTOR RB: Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am. J. Gastroen-terol. (1997) 92:5S–11S.
   Google Scholar
• STROBER W, KELSALL B, FUSS I et al.: Reciprocal IFNI and TGF-6 responses regulate the occurrence of muco-sal inflammation. Immunol Today (1997) 18:61–64.
   PubMedGoogle Scholar
• EHRHARDT R, LUDVIKSSON B, GRAY B et al.: Induction and prevention of colonic inflammation in IL-2 -def-icient mice. J. Immunol. (1997) 58:566–573.
   Google Scholar
• PETERSON RL, WANG L, ALBERT LM et al.: Molecular mechanisms of IL-11 in the HLA-B27 rat model of in-flammatory bowel disease. Gastroenterology (1998) 114:A1060.
   Web of Science ®Google Scholar
• VAN DEVENTER SJ, ELSON CO, FEDORAK RN: Multiple doses of intravenous IL-10 in steroid-refractory Crohn's disease. Crohn's disease study group. Gastro-enterology (1997) 113:383–389.
   PubMed Web of Science ®Google Scholar
• COMINELLLI F, NAST CC, CLARK BD et al.: Interleukin-1 (IL-1) gene expression, synthesis and effect of specific IL-1 receptor blockade in rabbit immune complex coli-tis. J. Clin. Invest. (1990) 86:972–980.
   PubMed Web of Science ®Google Scholar
• COMINELLI F, NAST C, LLERENA R et al.: Interleukin-1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins. J. Clin. Invest. (1990) 85:582–586.
   PubMed Web of Science ®Google Scholar
• CASSINI-RAGGI V, HERBERT C, MONSACCHI L et al.: A specific monoclonal antibody (MoAb) against interleukin-8 (IL-8) suppresses inflammation in rabbit immune colitis. Gastroenterology (1994) 106:A661.
   Web of Science ®Google Scholar
• DINARELLO CA, GELFAND JA, WOLFF SM: Anticytokine strategies in the treatment of the systemic inflamma-tory response syndrome. JAMA (1993) 269:1829–1835.
   PubMed Web of Science ®Google Scholar
• WATKINS PE, WARREN BF, STEPHENS S et al.: Treatment of ulcerative colitis in the cotton top tamarin using an-tibody to tumor necrosis factor. Gut (1997) 40:628–633.
   PubMed Web of Science ®Google Scholar
• NEURATH MF, FUSS I, PASPARAKIS M et al.: Predominant pathogenic role of tumor necrosis factor in experi-mental colitis in mice. Eur. j Immunol (1997) 27:1743–50.
   PubMed Web of Science ®Google Scholar
• MURTHY S, MEYER C, MEYER CJ et al.: Combined efficacy of TNEcc monoclonal antibody (Tmab) and pentoxifyl-line (PF) in dextran sulfate model of chronic colitis. Gastroenterolgy (1997) 112:A1048.
   PubMed Web of Science ®Google Scholar
• MURTHY S, FONDACARO JD, MURTHY NS, MINNICK M: Preclinical evaluation of novel elastase and TNF recep-tor inhibitors and antioxidants in dextran sulfate model of colitis in mice. Gastroenterology (1996) 110:A976.
   Web of Science ®Google Scholar
• MURTHY S, FLANIGAN A, TANAKA K eta].: Lymphotoxin beta receptor - immunoglobulin fusion protein (LTBRFP) ameliorates inflammation and tissue dam-age in the dextran sulfate (DSS) model of mouse colitis. Gastroenterology (1998) 114:G4282.
   Google Scholar
• VAN DULLEMEN HM, VAN DEVENTER SJH et al.: Treat-ment of Crohn's disease with anti-tumor necrosis fac-tor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 109:129–135.
   Google Scholar
• RUTGEERTS P, D'HAENS G, VAN DEVENTER SJ et al.: Re-treatment with anti-TNF-chimeric antibody (cA2) ef-fectively maintains cA2-induced remission in Crohn's disease. Gastroenterology (1997) 112:A1078.
   Google Scholar
• PRESENT D, MAYER L, VAN DEVENTER SJH et al.: Anti-TNF-alpha chimeric antibody (cA2) is effective in the treatment of the fistulae of Crohn's disease: a multi-center, randomised, double-blind, placebo-controlled study. Gastroenterology (1997) 112:A648.
   Google Scholar
• FEDORAK RN, GANGL A, ELSON CO et al.: Safety, toler-ance and efficacy of multiple doses of subcutaneous interleukin-10 in mild to moderate active Crohn's dis-ease (STAMM-CD). Gastroenterology (1998) 114:G3993.
   Web of Science ®Google Scholar
• SEMMLER J, WACHTEL H, ENDRES S: The specific Type IV phosphodiesterase inhibitor rolipram suppresses tu-mor necrosis factor-alpha production by human mononuclear cells. Intern. J. Immunopharmacol. (1993) 15:409–413.
   PubMed Web of Science ®Google Scholar
• FIERSTEIN GS, BOYLE D, BULLOUGH DA et al.: Protective effect of an adenosine kinase inhibitor in septic shock. Immunol (1994) 152:5853–5859.
   Web of Science ®Google Scholar
• MALININ NL, BOLDIN MP, KOVALENKO AV et al.: Map3K-related kinase involved in NF-kappaB induc-tion by TNF, CD95 and IL-1. Nature (1997) 385:540–544.
   PubMed Web of Science ®Google Scholar
• SANDER 0, RAU R: Long-term observations of 80 pa-tients treated with TNEcc receptor fusion protein (TNER55-IgGl, Roche 45-2081). Arthritis Rheum. (1997) 40:S224.
   Google Scholar
• WEINBLATT M, MORELAND LW, SCHIFF MH et al.: Long-term and Phase III treatment of DMARD failing rheu-matoid arthritis patients with TNFR p75fc fusion pro-tein (TNFR-fc:ENBREL). Arthritis Rheum. (1997) 40:S126.
   Google Scholar
• KHALED AR, BUTFILOSKI E, SOBEL E et al.: Use of NF-KB decoy or use of antisense oligodeoxynucleotide to the REL A subunit inhibits NF-KB expression and sup-presses the immune response. Arthritis Rheum. (1997) 40:S209.
   PubMedGoogle Scholar
• CONNER EM, FUSSLER JW, DAVUS JM et al.: Selective pro-teosome inhibition attenuates experimental polyar-thritis via inhibition of nuclear transcription factor KB (NEKB) activation. Arthritis Rheum. (1997) 40:S322.
   Google Scholar
• BADGER AM, BRADBEER JN, VOTTA B et al.: Pharma-cological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endo-toxin shock and immune infection. J. Pharmacol Exp. Ther. (1996) 279:1453–1461.
   PubMed Web of Science ®Google Scholar
• POWRIE F, LEACH MW, MAUZE S et al: Inhibition of Thl responses prevents inflammatory bowel disease in SCID mice reconstituted with CD45RBi1 CD4+ T cells. Immunity (1994) 1:553–562.
   PubMed Web of Science ®Google Scholar
• NEURATH MF, FUSS I, KELSALL BL et al: Antibodies to in-terleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. (1995) 182:1281–1290.
   PubMed Web of Science ®Google Scholar
• HANAUER SB: Aminosalicylate therapy for IBD. In: In-flammatory Bowel Diseases. Rachmilewitz D (Ed.), Kulwer Academic Publishers, Massachusetts (1994) 192–197.
   Google Scholar
• PULLEN RD, RHODES J, GANESH S et al: Transdermal nicotine for active ulcerative colitis. New Engl. J. Med. (1994) 330:811–805.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, TREMAINE WJ, OFFORD KP et al.: Trans-dermal nicotine for mildly to moderately active ulcera-tive colitis. A randomised, double- blind, placebo-controlled trial. Ann. Inter. Med. (1997) 126:364–371.
   PubMed Web of Science ®Google Scholar